Your browser doesn't support javascript.
loading
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes, Floor J; Wei, Lai; Chen, Min; Hill, Kasey; Dzwigalski, Kyle; Poi, Ming; Phelps, Mitch; Salani, Ritu; Copeland, Larry J; Fowler, Jeffrey M; Cohn, David E; Bixel, Kristin; Cosgrove, Casey; Hays, John; O'Malley, David.
  • Backes FJ; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States. Electronic address: Floor.backes@osumc.edu.
  • Wei L; Center of Biostatistics, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Chen M; Division of Pharmaceutics and Pharmacology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Hill K; Comprehensive Cancer Canter, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Dzwigalski K; Comprehensive Cancer Canter, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Poi M; Division of Pharmaceutics and Pharmacology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Phelps M; Division of Pharmaceutics and Pharmacology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Salani R; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States; David Geffen School of Medicine at UCLA, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Copeland LJ; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Fowler JM; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Cohn DE; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Bixel K; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Cosgrove C; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • Hays J; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
  • O'Malley D; Division of Gynecologic Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, United States.
Gynecol Oncol ; 162(3): 619-625, 2021 09.
Article en En | MEDLINE | ID: mdl-34272090
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de los Genitales Femeninos Límite: Aged / Female / Humans / Middle aged Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de los Genitales Femeninos Límite: Aged / Female / Humans / Middle aged Idioma: En Año: 2021 Tipo del documento: Article